Nykredit A S Purchases New Holdings in DexCom, Inc. $DXCM

Nykredit A S bought a new position in shares of DexCom, Inc. (NASDAQ:DXCM) during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund bought 141,032 shares of the medical device company’s stock, valued at approximately $9,499,000.

A number of other large investors have also modified their holdings of the business. MassMutual Private Wealth & Trust FSB increased its stake in DexCom by 15.4% during the second quarter. MassMutual Private Wealth & Trust FSB now owns 1,147 shares of the medical device company’s stock worth $77,000 after acquiring an additional 153 shares during the last quarter. V Square Quantitative Management LLC increased its position in shares of DexCom by 1.8% during the 1st quarter. V Square Quantitative Management LLC now owns 9,618 shares of the medical device company’s stock worth $604,000 after purchasing an additional 172 shares during the last quarter. Essex Financial Services Inc. raised its holdings in DexCom by 5.7% in the 1st quarter. Essex Financial Services Inc. now owns 3,256 shares of the medical device company’s stock valued at $204,000 after buying an additional 175 shares during the period. Keel Point LLC lifted its position in DexCom by 3.1% in the fourth quarter. Keel Point LLC now owns 6,473 shares of the medical device company’s stock valued at $430,000 after buying an additional 193 shares during the last quarter. Finally, Integrated Wealth Concepts LLC boosted its stake in DexCom by 6.3% during the first quarter. Integrated Wealth Concepts LLC now owns 3,329 shares of the medical device company’s stock worth $227,000 after buying an additional 196 shares during the period. Hedge funds and other institutional investors own 97.75% of the company’s stock.

Insider Buying and Selling at DexCom

In other DexCom news, EVP Michael Brown sold 1,700 shares of DexCom stock in a transaction that occurred on Monday, June 15th. The stock was sold at an average price of $75.55, for a total value of $128,435.00. Following the transaction, the executive vice president directly owned 106,353 shares in the company, valued at approximately $8,034,969.15. This trade represents a 1.57% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Kevin Sayer sold 26,756 shares of the stock in a transaction on Monday, July 20th. The stock was sold at an average price of $76.32, for a total value of $2,042,017.92. Following the sale, the insider directly owned 328,970 shares of the company’s stock, valued at approximately $25,106,990.40. This represents a 7.52% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 65,777 shares of company stock valued at $4,950,714 over the last ninety days. 0.28% of the stock is currently owned by corporate insiders.

DexCom Stock Down 2.0%

DexCom stock opened at $87.90 on Friday. DexCom, Inc. has a fifty-two week low of $54.11 and a fifty-two week high of $92.59. The company has a debt-to-equity ratio of 0.47, a quick ratio of 1.43 and a current ratio of 1.73. The company has a market capitalization of $33.17 billion, a P/E ratio of 34.74, a PEG ratio of 1.47 and a beta of 1.42. The stock has a 50-day simple moving average of $81.24 and a 200-day simple moving average of $72.35.

DexCom (NASDAQ:DXCM) last released its quarterly earnings results on Thursday, July 30th. The medical device company reported $0.70 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.61 by $0.09. The firm had revenue of $1.31 billion for the quarter, compared to the consensus estimate of $1.29 billion. DexCom had a return on equity of 35.94% and a net margin of 20.12%.The firm’s quarterly revenue was up 13.1% compared to the same quarter last year. During the same quarter last year, the business posted $0.48 EPS. Equities research analysts expect that DexCom, Inc. will post 2.64 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of analysts have issued reports on DXCM shares. Wall Street Zen raised DexCom from a “hold” rating to a “buy” rating in a research report on Sunday. Argus boosted their price objective on DexCom from $86.00 to $96.00 and gave the company a “buy” rating in a report on Tuesday, August 4th. Royal Bank Of Canada increased their target price on DexCom from $85.00 to $90.00 and gave the stock an “outperform” rating in a research note on Friday, July 31st. Canaccord Genuity Group set a $90.00 target price on DexCom and gave the company a “buy” rating in a report on Monday, August 3rd. Finally, William Blair upgraded shares of DexCom to a “strong-buy” rating in a research note on Friday, May 15th. Two analysts have rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating, three have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, DexCom has a consensus rating of “Moderate Buy” and an average target price of $88.71.

DexCom Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.